Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 72.1% in the 4th quarter, Holdings Channel reports. The firm owned 43,844 shares of the company’s stock after purchasing an additional 18,364 shares during the period. SG Americas Securities LLC’s holdings in Ginkgo Bioworks were worth $74,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. ARK Investment Management LLC grew its stake in Ginkgo Bioworks by 7.3% during the 3rd quarter. ARK Investment Management LLC now owns 182,192,185 shares of the company’s stock valued at $329,768,000 after acquiring an additional 12,442,658 shares in the last quarter. Vanguard Group Inc. grew its stake in Ginkgo Bioworks by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 132,316,999 shares of the company’s stock valued at $239,494,000 after acquiring an additional 4,016,221 shares in the last quarter. BlackRock Inc. grew its stake in Ginkgo Bioworks by 34.6% during the 2nd quarter. BlackRock Inc. now owns 68,202,832 shares of the company’s stock valued at $126,857,000 after acquiring an additional 17,538,752 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Ginkgo Bioworks by 15.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 58,746,160 shares of the company’s stock valued at $106,331,000 after acquiring an additional 7,958,613 shares in the last quarter. Finally, State Street Corp grew its stake in Ginkgo Bioworks by 40.6% during the 2nd quarter. State Street Corp now owns 20,683,752 shares of the company’s stock valued at $38,472,000 after acquiring an additional 5,976,244 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

Ginkgo Bioworks stock opened at $0.86 on Friday. The firm has a 50 day simple moving average of $1.19 and a 200-day simple moving average of $1.37. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $0.85 and a 1-year high of $2.55. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -1.84 and a beta of 1.35.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The firm had revenue of $34.76 million during the quarter, compared to analysts’ expectations of $40.37 million. During the same period last year, the company earned ($0.04) EPS. The business’s quarterly revenue was down 64.6% on a year-over-year basis. Equities analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.32 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mark E. Dmytruk sold 51,169 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total value of $53,727.45. Following the transaction, the insider now directly owns 865,079 shares in the company, valued at approximately $908,332.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Mark E. Dmytruk sold 51,169 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total value of $53,727.45. Following the transaction, the insider now directly owns 865,079 shares in the company, valued at approximately $908,332.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark E. Dmytruk sold 39,569 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total transaction of $47,878.49. Following the completion of the transaction, the insider now owns 761,737 shares in the company, valued at $921,701.77. The disclosure for this sale can be found here. Corporate insiders own 15.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. The Goldman Sachs Group dropped their price objective on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research note on Monday, January 22nd. TD Cowen dropped their price objective on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Hold” and a consensus price target of $2.20.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.